(Q37547257)

20 August 2017

1 reference

title

Overview of biologic therapy for Crohn's disease (English)

1 reference

20 August 2017

0 references

0 references

Gerald W Dryden

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Biological Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

967-974

1 reference

The fundamental basis of inflammatory bowel disease

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Resource use in patients with Crohn's disease treated with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

TNF/TNFR family members in costimulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Alterations of mesenchymal and endothelial cells in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Leukocyte adhesion molecules in animal models of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Increasing yield also increases false positives and best serves to exclude GERD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Adalimumab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

CTLA4Ig: a novel inhibitor of costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Safety of biologic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903048909

10.1517/14712590903048909

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference